Global AI-Enabled Imaging Modalities Market to Reach $2.64 Billion by 2030

Global AI-enabled imaging modalities market is currently witnessing a significant change in the market landscape. There is rising investment in development of healthcare infrastructure, increasing evidences for efficient and promising results in treatment and diagnosis assistance. Thus, this is leading to potential growth opportunities for the AI-enabled imaging modalities market. Moreover, there is an extensive entry of emerging players developing AI powered imaging systems, and software companies into the healthcare space. All these predominant factors have led to a significant rise in sales of AI-based imaging modality systems across the globe.

Global AI-Enabled Imaging Modalities Market Forecast, 2020-2030

The global AI-enabled imaging modalities market was valued at $214.4 million in 2019 and is anticipated to reach $2,649.6 million by 2030, growing at a CAGR of 23.32%, during the forecast period 2020-2030. The increasing complexities in clinical decision making, rising radiologist workload, and huge R&D investments are the major factors fueling the market growth. In addition to these factors, there are significant challenges and restraints, which are restricting the market growth. These challenges include the physicians’ reluctance toward the adoption of advanced technologies such as AI and the privacy and security concerns related to healthcare data. Hence, it is anticipated that these trends will have a significant impact on healthcare service robots market in the next five years, and the market will grow multifold.

Competitive Landscape

The global AI-enabled imaging modalities market consists of numerous large-scale as well as small-scale manufacturers and vendors. Presently, with the increasing adoption of AI in healthcare, the manufacturers in the market have ample number of opportunities to expand their offerings and to establish a strong foothold in the market.

During February 2016-July 2020, the market witnessed approximately 40 new offerings, 32 partnerships, alliances & business expansions, 27 regulatory & legal approvals, 13 funding activities, six mergers & acquisition, and one procurement & sales.

Most of the manufacturers in the market are incorporating collaborations and partnerships with not only other companies but also the university and research institutions as the key strategies to develop novel AI-embedded medical imaging systems and attain a strong financial position in the market.

The key players contributing to the global AI-enabled Imaging modalities market are Koninklijke Philips N.V., Siemens Healthineers AG., General Electric Company, Canon, Inc., Butterfly Network, Inc., Hyperfine, United Imaging Healthcare, Exo, Yorlabs, Agfa-Gevaert Group, Hologic, Inc, Fujifilm, Konica Minolta, Inc., Nanox, and Tissue Differentiation Imaging (TDI), among others.

Key Questions Answered in this Report:

•   What are the various AI-enabled imaging modalities and systems available in the market?
•   What is the current market size and future potential of these products?
•   What are the major market drivers, challenges, and opportunities in the global AI-enabled imaging modalities market?
•   What are the guidelines implemented by different government bodies to regulate the approval of AI-enabled imaging modalities?
•   What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
•   Who are the leading players holding dominating shares in the global AI-enabled imaging modalities market, currently?
•   What are the key strategies incorporated by the players of global AI-enabled imaging modalities market, to sustain the competition and retain their supremacy?
•   What is the current revenue contribution of different modality types and how are these contributions expected to evolve in the forecast period?
•   What is the current revenue contribution of different therapeutic applications and how are these contributions expected to be evolved in the forecast period?
•   What is the current demand contributions of different workflow types and how are these contributions expected to evolve in the forecast period?
•   Which countries contribute to the major share of current demand and which countries hold significant scope for expansion for business activities, by players of the global AI-enabled imaging modalities market?

Request a Sample - https://bisresearch.com/requestsample?id=977&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog